2017 U.S. Adult Immunization Schedule

摘要

Sponsoring Organization: Advisory Committee on Immunization Practices (ACIP) Target Audience: All U.S. clinicians Background The ACIP has released its 2017 recommendations for immunizing adults (age, >19). This year’s schedule includes changes, all relatively minor, in rules for administering influenza, human papillomavirus (HPV), and meningococcal vaccines. What’s Changed? The live attenuated flu vaccine should not be given during the current influenza season. Even adults with severe egg allergy can receive the inactivated or recombinant preparations if suitable precautions are taken. The HPV vacdne schedule has been modified to reflect the new finding that adolescents who start the series before age 15 are fully immunized after two doses rather than three, as previously recommended. The serogroup B meningococcal vaccine MenB-FHbp (Trumenba) should be given in three doses (at 0,1-2, and 6 months) only when used during outbreaks or when given to adults at elevated risk for meningococcal disease. Otherwise, this vaccine can be given in two doses at 0 and 6 months. The other group B preparation, MenB-4C (Bexsero), still should be given in two doses at least 1 month apart. The guideline emphasizes that these two vaccines are not interchangeable, and all courses should consist of one preparation or the other, not both.